By Stephen Nakrosis

Shares of Verve Therapeutics, Inc. have been decrease in Wednesday’s late buying and selling market after the corporate stated it commenced an underwritten public providing of $200 million of frequent inventory.
All shares are being supplied by Verve, the corporate stated.

At 5:09 p.m. EDT, the corporate’s shares had fallen 14.45% to commerce at $30.72 per share. The inventory completed the day’s common session with an 11.21% achieve at $35.91 per share.
Additionally on Wednesday, the corporate stated it entered a worldwide analysis collaboration with Vertex Prescribed drugs, Inc. to find and develop an in vivo gene modifying program for a single undisclosed liver illness.
Verve has a market cap of $1.57 billion, 48.66 million shares excellent and a public float of 25.05 million shares.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com